Evidence map›Paper›PMID 29624739›Full record

ReviewSeminars in dialysis2018

Hemodialysis-induced cardiovascular disease.

Shadi Ahmadmehrabi, W H Wilson Tang

Registry-linked trialAbstract readReview
In one paragraph

Review in Seminars in dialysis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07459348 (Can Changes in Dialysate Sodium Concentration Improve Blood Pressure and Endothelial Function in Patients Undergoing Chronic Hemodialysis?), which is not on this map. Cited by 101 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07459348 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Can Changes in Dialysate Sodium Concentration Improve Blood Pressure and Endothelial Function in Patients Undergoing Chronic Hemodialysis?

TypeinterventionalSponsorGødstrup HospitalRan2026 to 2029Enrolled25ConditionsDialysis Dependent Chronic Kidney Disease, Dialysis Patients, Sodium Excess, High Blood PressureArmsLow-Sodium Dialysate (133 mmol/L), Standard-Sodium Dialysate (139 mmol/L)
3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Observational
  17. Cardiovascular Biomarkers in Nocturnal Hemodialysis and Their Association With Physical Performance.Hemodialysis international. International Symposium on Home Hemodialysis · 2025
    Article
  18. Article
  19. Article
  20. Article

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shadi AhmadmehrabiCleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland, OH, USA.
W H Wilson TangDepartment of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA.

Funding

Diet, Gut Microbiota, and Heart FailureR01HL126827 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI HAZEN, STANLEY L, TANG, WAI HONG WILSON · 2016 to 2019
$3.1M
Dietary Choline, Gut Microbiota, and Susceptibility for Chronic Kidney DiseaseR01DK106000 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI HAZEN, STANLEY L, TANG, WAI HONG WILSON · 2015 to 2018
$2.8M
NHLBI NIH HHS R01 HL126827NIDDK NIH HHS R01 DK106000
6 · The paper itself

Abstract

More than half of all deaths among end stage renal disease (ESRD) patients are due to cardiovascular disease (CVD). Cardiovascular changes secondary to renal dysfunction, including fluid overload, uremic cardiomyopathy, secondary hyperparathyroidism, anemia, altered lipid metabolism, and accumulation of gut microbiota-derived uremic toxins like trimethylamine N-oxidase, contribute to the high risk for CVD in the ESRD population. In addition, conventional hemodialysis (HD) itself poses myocardial stress and injury on the already compromised cardiovascular system in uremic patients. This review will provide an overview of cardiovascular changes in chronic kidney disease and ESRD, a description of reported mechanisms for HD-induced myocardial injury, comparison of HD with other treatment modalities in the context of CVD, and possible management strategies.

Indexed as

Cardiovascular DiseasesFemaleHumansIncidenceKidney Failure, ChronicMalePrognosisRenal DialysisRisk Assessment

Identifiers

PMID29624739
PMCPMC6023623

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.